dpp4i and glp 1 agonist DPP-4 inhibitors GLP-1RAs: cardiovascular safety and benefits | Military Medical Research GLP-1-RA and DPP-4 inhibitors in
Description
Treatment of diabetic retinopathy

BuseJBKlonoffDCNielsenLLGuanXBowlusCLHolcombeJHet al

There was also a significant decrease in the VAT area (32.31 cm)

Sustainalytics dual-scoring Controversy research highlights how current market leaders Novo and Lilly are involved in a combined multi-district litigation over their GLP-1 drugs alleged link to gastrointestinal injuries, underscoring ongoing legal risks and associated impact safety risks

2025 Jan;48(Supplement_1):S26682
